ASCENTAGE-B (06855) announced that it will present four preclinical research findings in poster sessions at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference is scheduled to take place from April 17 to April 22, 2026, in San Diego, California, USA.

The poster presentations will cover three of the company's drug candidates. These include the proprietary Class 1 novel drug Olverembatinib (brand name: Nirlivek®; R&D code: HQP1351), a BCR-ABL inhibitor; APG-2449, a triple tyrosine kinase inhibitor targeting FAK/ALK/ROS1; and APG-5918, a PRC2/EED inhibitor.

A key highlight is the demonstration of Olverembatinib's potential beyond chronic myeloid leukemia (CML), showcasing new applications in areas such as endometrial cancer (EC) and mantle cell lymphoma (MCL), as well as combination therapy strategies with BTK inhibitors.

Furthermore, the company's research on APG-2449 for BRAF-mutant tumors and on APG-5918 for small cell lung cancer underscores its strategic focus on overcoming drug resistance mechanisms and exploring combination treatment approaches.